Neosalvarsan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Neosalvarsan
Neosalvarsan.svg
Neosalvarsan-3D-vdW.png
Names
Other names
Sodium 3,3'-diamino-4,4'-dihydroxyarsenobenzene-N-formaldehydesulfoxylate; Neoarsphenamine;914
Identifiers
457-60-3 YesY
ChemSpider 9586 YesY
Jmol-3D images Image
PubChem 9980
UNII O7K7R0O4BG YesY
Properties
C13H13As2N2NaO4S
Molar mass 466.15 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
 YesY verify (what isYesY/N?)
Infobox references

Neosalvarsan is a synthetic chemotherapeutic that is an organoarsenic compound. It became available in 1912 and superseded the more toxic and less water-soluble salvarsan as an effective treatment for syphilis. Because both of these arsenicals carried considerable risk of side effects, they were replaced for this indication by penicillin in the 1940s.

Both salvarsan and neosalvarsan were developed in the laboratory of Paul Ehrlich in Frankfurt, Germany. Their discoveries were the result of the first organized team effort to optimize the biological activity of a lead compound through systematic chemical modifications.[1] This scheme is the basis for most modern pharmaceutical research. Both salvarsan and neosalvarsan are prodrugs — that is, they are metabolised into the active drug in the body.

References[edit]

  1. ^ Strebhardt K, Ullrich A (May 2008). "Paul Ehrlich's magic bullet concept: 100 years of progress". Nat. Rev. Cancer 8 (6): 473–80. doi:10.1038/nrc2394. PMID 18469827.